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Abstract: Differentiation is a complex process by which cells become specialized in their physiological functions. As 
this process is followed by a decrease in proliferation ability, the induction of differentiation could be an ideal cancer 
treatment. We analyzed the effects of a common differentiation agent, retinoic acid, on neuroblastoma SH-SY5Y cells 
under the conditions of poly(ADP-ribose) polymerase (PARP) inhibition. Namely, PARP1 can be indirectly involved in 
processes of chromatin remodelling, so the aim was to investigate whether its inhibition can influence the process of 
differentiation. Cells differentiated after retinoic acid treatment into neural cells, with neurite outgrowth, proliferation 
arrest and induction of tissue plasminogen activator. PARP inhibition did not influence the process of differentiation. 
Analysis of gene expression revealed the involvement of several signaling pathways in RA-dependent differentiation. 
Beside TGFβ and Notch pathways, master transcription factors directing epithelial-mesenchymal transition were shown 
to also take part in the differentiation process.  
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Up to now, one of the most successful tumor therapies 
applied is the treatment of some forms of 
promyelocytic leukaemia by derivates of retinoic acid 
(RA; all-trans retinoic acid ATRA), inducing B cell 
differentiation. Other types of tumors and leukemia are 
mostly refractive to differentiation.
1, 2
  This is also true 
for a group of neuro and glioblastoma tumors: these 
tumors usually exhibit very aggressive behavior, but a 
subset of neuroblastoma cell lines can be differentiated 
by retinoic acid.
3, 4
 Retinoic acid is a steroid, binding as 
a ligand to its receptors (RAR and RAX) in the 
nucleus, where the complex acts as a transcription 
factor. RA was also found to be able to interfere with 
peroxisome proliferator-activated receptor pathways 
(PPAR), but in dependence on the intracellular milieu. 
RA has a role in neurogenesis and neural stem cell 
differentiation. It mediates the proliferation-
differentiation switch through a complex network 
including interactions with the Notch pathway, 
proneural and neurogenic proteins and genes involved 
in neural proliferation.
5
 Pathways involved in 
embryonic stem cell differentiation toward neuronal 
tissue by RA also require the activation of several 
pathways, including Wnt, MAP kinases, Src kinases, 
inhibition of GSKβ and others.6  
In this article, we analyzed the influence of poly(ADP-
ribosyl)polymerase (PARP) inhibition on the RA-
induced differentiation process. PARP1 is an enzyme 
which adds ADP-ribose chains on proteins, and thus 
causes changes in the chromatin structure and 
facilitates the process of DNA damage repair. Its 
activation in the case of DNA damage can direct cells 
toward apoptosis or necrosis. Its participation in 
different processes of chromatin remodeling and cell 
differentiation is still being uncovering. PARP1 
modifies a number of transcription factors and some of 
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them are involved in differentiation processes. It can 
influence the processes of DNA methylation and take 
part in insulator regulation. Also, it was found that it 




We analyzed the expression of a set of genes involved 
in differentiation and epithelial-mesenchymal transition 
in a neuroblastoma cell line, after treatment with RA 
and the PARP inhibitor for a prolonged time period. 
SH-SY5Y cells are model cells for RA-dependent 
differentiation, a process which requires prolonged 
treatment and involves numerous changes in cell 
biology, including signaling pathways and gene 
expression, cell morphology and proliferation. As 
PARP1 has the ability to change the chromatin and 
influence the activity of a number of transcription 
factors, we wanted to see whether it could influence the 
process of SH-SY5Y differentiation. 
 
 
MATERIAL AND METHODS 
Cell culture and growth assessment 
Neuroblastoma SH-SY5Y cells were grown in 
DMEM/F12 (50:50) medium (Gibco, USA) 
supplemented with 10% fetal bovine serum (Sigma, 
USA) at 37 
o
C and 5% CO2.  The cell line is 
commercially available at ATCC (USA). Cells were 
tested for the presence of mycoplasma with EZ-PCR 
Mycoplasma Test Kit (Biological Industry, Israel). 
Cells were treated with ATRA (all-trans retinoic acid) 
(Sigma) and PJ-34, PARP inhibitor (Sigma). Control 
cells were treated with DMSO (Sigma). For prolonged 
treatment, cells were treated with 10 µM ATRA and  
20 µM PJ-34 every second day and reseeded if needed. 
Cell growth was assessed by crystal violet staining. 
Cells were seeded on a 96-well plate in multiplicates, 
and every second day one set of cells was fixed with 
cold methanol. At the end of the assay, the plate was 
stained with crystal violet and after dissolving in 1% 





Measurement of neurite length 
To measure the length of neurite outgrowth in cells, 
cells were photographed on the inverted microscope 
(Zeiss Axiovert 40 CFL) every second day. The neurite 
length was analysed with NeuroGrowth software in 
ImageJ program (NIH, USA). 
 
 
RNA preparation, cDNA synthesis and quantitative 
real-time PCR 
Total RNA was extracted from cells using TRI Reagent 
(Sigma), and cDNA was synthesized from 2µg of total 
RNA by Primescript RTase (Takara, Japan) according 
to the manufacturer’s instructions. Quantitative real-
time PCR (qRT-PCR) was performed using GoTaq® 
qPCR Master Mix (Promega, USA) in 7500 Fast Real-
Time PCR system (Applied Biosystems, USA). Gene 
expression was validated by comparison with HPRT 
gene expression. Primer sequences, designed by IDT 
PrimerQuest software package (Integrated DNA 
Technologies, Inc., USA) used for PCR reactions, are 
listed in Table 1. 
 
 








F: 5’-CTGCTTAGACGCTGGATTT-3'  
R: 5’-CTCCTCGTCGCAGTAGAAA-3' 
SMAD4 
F: 5’-CGCGGTCTTTGTACAGAGTTA-3’  
R: 5’-GATGACACTGACGCAAATCAAA-3’ 
SMAD7 
F: 5’-ACCCGATGGATTTTCTCAAACC-3’  
R: 5’-GCCAGATAATTCGTTCCCCCT-3’ 
SNAIL1 
F: 5’-TCTAGGCCCTGGCTGCTACA-3’  
R: 5’-CATCTGAGTGGGTCTGGAGGT-3’ 
SNAIL2 
F: 5’-CCTGGTCAAGAAGCATTTCAAC-3’  
R: 5’-GAGGATCTCTGGTTGTGGTATG-3’ 
TGFβ 
F: 5’-GACACCAACTATTGCTTCAG’-3’  
R: 5’-AGAAGTTGGCATGGTAGCCC-3’ 
TWIST1 
F: 5'-CGGAGACCTAGATGTCATTGTTT-3'  
R: 5'-ACGCCTGTTTCTTTGAATTTG-3' 
ZEB1 
F: 5’-GGCAGATGAAGCAGGATGTA-3’  
R: 5’-GACAGCAGTGTCTTGTTGTTG-3’ 
tPA 
F: 5'-CTGGGAAGTGCTGTGAAATA-3'  




Data were statistically analyzed using the software 
package Microsoft Office and R Statistical Software 
(The R Foundation). The parametric test was used for 
comparison of gene expression between control and 
treated cells. The significance of independent two-
tailed Student’s t-test was set at P-value < 0.05. Neurite 
growth was analyzed using ANOVA and post-hoc 




The effect of ATRA treatment and PARP inhibition 
on growth and differentiation of SH-SY5Y 
neuroblastoma cells 
It was found that RA induced differentiation in a set of 
neuroblastoma cell lines, such as SH-SY5Y, SK-N-SH, 
LA-N-5 etc.
9-11
 We chose SH-SY5Y cells and treated 
them for up to 9 days by RA alone  and in combination 
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Figure 1.  A: Growth curve of SH-SY5Y cells treated with ATRA and PARP inhibitor. 
Cells were treated every second day with 10 µM ATRA 
and 20 µM PJ-34 and their combination. Cell proliferation was determined by crystal violet staining and absorbance measurement. 
B: Morphology of SH-SY5Y cells after 7 days of treatment with ATRA and PARP inhibitor. 
Microphotographs were taken with the epifluorescent microscope Axiovert 40 CFL (Zeiss). a: control; b: cells treated with 20 µM PJ-34; 
c: cells treated with 10 µM ATRA; d: cells treated with 10 µM ATRA and 20 µM PJ-34. 
C: Neurite length in SH-SY5Y cells after treatment with ATRA and PARP inhibitor. 
Neurite length was analysed on microphotographs by ImageJ program, after one (a) and seven days (b). * the mean values were 
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with the PARP inhibitor PJ-34, in order to see whether 
inhibition of PARP1 could possibly influence 
chromatin structure and the process of differentiation. 
To analyze the proliferation of SH-SY5Y cells, the 
cells were monitored for 6 days while being treated 
with 10 µM ATRA and 20 µM PJ-34 PARP inhibitor, 
alone or in combination every other day. Cell 
proliferation was assessed by crystal violet staining and 
absorption measurement. Results (Fig. 1) showed that 
cells treated with ATRA alone or in combination with 
the PARP inhibitor stopped proliferating soon after the 
beginning of the treatment, and their number remained 
the same throughout the experiment. After 6 days, 
growth inhibition was around 90% in comparison to 
untreated cells. Cells treated with the PARP inhibitor 
alone did not show significant proliferation inhibition 
(Fig. 1A), nor did PARP inhibition influence the cell 
arrest observed in RA-treated cells.  
Even 24 h after the beginning of the treatment with 
ATRA, SH-SY5Y cells showed an increase in neurite 
length as a sign of differentiation. Fig. 1B shows that 
cell morphology changed on the 7th day of treatment 
when phenotype differences reached the maximal level. 
ATRA-treated cells had longer neurites in comparison 
with untreated cells, and the PARP inhibitor did not 
influence this process significantly, nor did it prolong 
the neurites when applied alone (Fig. 1C). 
 
The effect of ATRA and PARP inhibition on gene 
expression in SH-SY5Y neuroblastoma cells 
Effects of ATRA and PARP inhibitor on SH-SY5Y 
cells were also explored on the level of mRNA 
expression after 9 days of treatment (Fig. 2).  The most 
prominent change was the upregulation of a molecule 
characteristic for differentiated cells, the tissue 
plasminogen activator (tPA).
12
 In the cells treated with 
ATRA, its expression was increased hundredfold and 
the PARP inhibitor did not influence this induction. 
Analysis of c-MYC expression, as it illustrates the cell's 
growth and differentiation potential, showed c-MYC 
downregulation by 70% in differentiated cells. A set of 
genes involved in signaling pathways of differentiation 
programs was also investigated, such as TGFβ and 
downstream targets of its signaling. TGFβ was 
increased seven times in differentiated cells, as well as 
SMAD7, involved in the negative feedback loop and 
TGFβ downstream target. A downstream target of 
Notch signaling, involved in neural differentiation, 
HES1, was also upregulated. The third group of genes 
examined were master transcription factors involved in 
the epithelial-mesenchymal transition: TWIST, SNAIL1, 
SNAIL2 and ZEB1. SNAIL1 and SNAIL2 were 









Figure 2.  qRT-PCR analysis of expression of genes involved in the differentiation process in SH-SY5Y cells, after 9 days of ATRA and PJ-34 
treatment. 
Cells were treated with 10 µM ATRA and 20 µM PJ-34 and their combination every second day. After 9 days, RNA was isolated and 
cDNA prepared. Relative expression level was normalized with hypoxanthine-guanine phosphoribosyltransferase (HPRT) and presented 
relative to untreated control cell values. Data are expressed as mean ± SD. control: untreated control cells; PJ-34: cells treated with PARP 
inhibitor; ATRA: cells treated with ATRA; PJ-34/ATRA: cells treated with ATRA and PARP inhibitor. tPA: tissue plasminogen activator 
* the mean values were significantly different from control according to Student's t-test (p≤0.05). 
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DISCUSSION 
Differentiation is an extremely complex process of 
sequential cellular reprogramming, leading to a cell 
specialized for performing specific activities, but with 
low proliferation capacity. Tumor cells, on the other 
hand, go through the process of dedifferentiation or 
retain features of undifferentiated cells with high 
proliferation capacity. Consequently, one of the aims of 
antitumour therapy is the induction of differentiation. 
Considering that ATRA is often used as a 
differentiation agent,
4
 we investigated its effects on a 
neuroblastoma cell line, alone and in combination with 
the PARP inhibitor, treating cells over a prolonged 
time period. 
Our results showed that ATRA induced differentiation 
in neuroblastoma SH-SY5Y cells, as was shown 
previously by other authors.
11, 14
 Differentiation by 
ATRA resulted in inhibition of proliferation and 
changes in cell morphology. Analysis of gene 
expression revealed high expression of tissue 
plasminogen activator, which is characteristic for 
differentiated cells.
12
 Although the primary function of 
tPA is considered to be plasminogen activation and 
ECM degradation through plasmin proteolysis, it was 
found to act as a neuromodulator in neurons and glial 
cells. It can regulate synaptic plasticity and neuronal 
survival and influence the release of different growth 
factors from the ECM, such as guidance molecules F-
spondin and VEGF.
15-17
 It was also shown that tPA 
regulated neurite outgrowth in neural progenitor cells 
through wnt-β catenin signaling, and therefore could 
have an active role in cell differentiation.
18
 
We also detected a decrease in c-MYC expression that 
correlated with growth inhibition. Both of these genes 
could be found in a list of genes upregulated or 
downregulated by ATRA respectively, in SH-SY5Y 
cells, obtained by microarray analysis done by Korecka 
et al.
14
 In differentiated cells, an increase in TGFβ, as 
well as SMAD4 and negative feedback element SMAD7 
expression was detected. TGFβ pathway could 
participate in a differentiation process, as was recently 
reported by Duffy et al.
19
 PARP inhibition did not 
influence TGFβ expression in these cells, although 
PARP was found to modulate Smad transcription 
ability.
20, 21
 We detected high induction of HES1 which 
could mirror the activity of the Notch pathway. Notch 
signaling was found to be involved in embryonic stem 
cell differentiation toward neural cells,
22, 23
 and 
microarray analysis of SH-SY5Y cells showed an 
increase in HES1 and NOTCH2.
14
 We also detected an 
increase in SNAIL1 and SNAIL2 expression, while 
TWIST and ZEB1 remained on the control level. 
Microarray data confirmed the increase in these two 
genes after ATRA treatment.
14
 Ferarri-Toninelli et al
24
 
observed increased migration in SH-SY5Y induced by 
ATRA, which could be a consequence of SNAIL1 and 
SNAIL2 mRNA increase. Joshi et al
25
 found the 
increase in activity of small Rho GTPases and MMP9, 
as well as increased invasiveness in SH-SY5Y cells 
after 24 h-treatment with ATRA. Transcriptional 
profiling of ATRA-treated SH-SY5Y cells led to the 
conclusion that cells enter a pro-differentiation 
transcriptional state and develop a predominantly 




PARP inhibition did not influence the process of RA-
dependent differentiation of SH-SY5Y cells, as could 
be concluded from the growth curve and expression 
analysis. PARP influence possibly depends on the 
intracellular milieu and has a dominant role at certain 
time points during differentiation. We also cannot 
exclude its interference with some signaling pathways 
which were not analyzed and which did not affect the 
overall cell fate but participate in the fine-tuning of 
gene expression. Joshi et al
25
 found PARP1 to 
influence the process of embryo implantation under the 
control of steroid hormone oestradiol in mice. It was 
also found to influence the ability of proliferation and 
self-renewal in neural stem/progenitor cells through 
p53 pathway modulation .
26
 PARP1 was also found to 
regulate the expression of pluripotency stem cell 
factors, fine-tune transcription and preserve the 
capacity for developmental plasticity of embryonal 
stem cells.
27-30
 In neuroblastoma, it was found that their 
differentiation status depended on PARP1 cooperation 
with the protein PHF20 which led to increased 
stemness and aggressiveness.
31
 Considering the 
modification of transcription factors, PARP1 was 
found to interfere with the TGFβ pathway, influencing 
the duration of Smad signaling.
20
 In SH-SY5Y cells we 
could not detect such processes, indicating a cell-
specific set of signaling pathways influenced by 
PARP1.  
The resistance of RA-induced differentiation on PARP 
inhibition could also be analyzed in the context of 
tumor therapy. Namely, some PARP inhibitors, such as 
olaparib, are used for targeted therapy of tumors with 
defects in certain DNA damage repair mechanisms.
32
 
Therefore, it is important to understand the biology of 
PARP in the process of cell differentiation in different 
tissues and cell types. 
To conclude, in SH-SY5Y neuroblastoma cells RA can 
trigger the process of differentiation characterized by 
extensive changes in cell proliferation, morphology and 
gene expression. This process includes numerous 
signaling pathways which mutually cooperate and 
sequentially further induce each other. PARP inhibition 
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